Analysts predict that Veru Inc (NASDAQ:VERU) will report $9.26 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Veru’s earnings, with estimates ranging from $8.20 million to $11.19 million. Veru posted sales of $5.20 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 78.1%. The company is expected to issue its next quarterly earnings report on Thursday, December 12th.
On average, analysts expect that Veru will report full-year sales of $32.35 million for the current year, with estimates ranging from $31.30 million to $34.26 million. For the next financial year, analysts forecast that the business will report sales of $34.96 million, with estimates ranging from $33.90 million to $35.97 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Veru.
Veru (NASDAQ:VERU) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The firm had revenue of $9.73 million during the quarter, compared to analyst estimates of $8.11 million. Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%.
In other news, insider Mitchell Shuster Steiner sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $2.26, for a total transaction of $67,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michele Greco acquired 20,000 shares of Veru stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average price of $1.84 per share, with a total value of $36,800.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 47,000 shares of company stock valued at $89,040 and have sold 90,000 shares valued at $189,158. 29.50% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC increased its stake in Veru by 1.4% in the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock valued at $3,078,000 after purchasing an additional 20,000 shares in the last quarter. BlackRock Inc. increased its stake in Veru by 65.4% in the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after purchasing an additional 90,530 shares in the last quarter. Renaissance Technologies LLC increased its stake in Veru by 183.1% in the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after purchasing an additional 169,550 shares in the last quarter. Finally, Wedge Capital Management L L P NC purchased a new position in Veru in the 2nd quarter valued at approximately $394,000. Institutional investors and hedge funds own 8.83% of the company’s stock.
Veru stock traded up $0.04 during midday trading on Monday, hitting $2.15. The stock had a trading volume of 12,981 shares, compared to its average volume of 159,189. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.13. The stock has a market cap of $139.83 million, a P/E ratio of -5.51 and a beta of 0.41. Veru has a 12 month low of $1.18 and a 12 month high of $2.49. The business has a fifty day moving average price of $2.01 and a 200 day moving average price of $1.90.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Recommended Story: What are benefits of a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.